AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00817843
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 weeks of treatment with simvastatin 80 mg
Trial: NCT00817843
Drug: Simvastatin/Ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 weeks of treatment with simvastatin 10 mg / ezetimibe 10 mg combination
Trial: NCT03931941
Drug: RBX2660
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBX2660 is a microbiota suspension administered as an enema
Trial: NCT03476642
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection of 20mL epinephrine in combination with ropivacaine at the left or right T5 transverse process
Trial: NCT03982121
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²
Trial: NCT00563875
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/d for 7 days (healthy volunteers) and continued treatment with 75 mg/d in patients taking daily aspirin.
Trial: NCT01569191
Drug: Anti-allergic Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop on single occasion after exposure to grass pollen
Trial: NCT03809702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
Trial: NCT02285699
Drug: SSRIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-weeks of standard SSRi treatment for those interested in Phase II of the study.
Trial: NCT00499733
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2 of cyclophosphamide is infused via intravenous route three days post cryoablation surgery.
Trial: NCT03931928
Drug: (Z)-Endoxifen supplementation according to genotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: CYP2D6 genotype predicted intermediate metabolizer receive 1.5 mg, poor metabolizer receive 3 mg (Z)-Endoxifen and extensive or ultrarapid metabolizer receive 0 mg endoxifen (Placebo)
Trial: NCT00532233
Drug: QAX576
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00635804
Drug: MK-3281
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)
Trial: NCT00635804
Drug: Placebo to MK-3281
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched placebo to MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose of MK-3281 in serial panel. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
Trial: NCT00612573
Drug: Doxycycline 0.6 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxycycline 40 mg/day, oral, 12 weeks
Trial: NCT00612573
Drug: Doxycycline 1.2 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxycycline 80 mg/day, 12 weeks
Trial: NCT00612573
Drug: Doxycycline 2.4 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxycycline 160 mg/day, 12 weeks
Trial: NCT00612573
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 12 weeks
Trial: NCT03606018
Drug: Humalog® Mix 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: insulin lispro biphasic in doses 0.4 ME/kg
Trial: NCT03371667
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Methotrexate will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103.
Trial: NCT04318015
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All placebo will be administered orally
Trial: NCT03371667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Placebo will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103.
Trial: NCT02701374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00568022
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: Tablets, Oral, 1650(2000)mg/m\^2, twice daily for 2 weeks, one week off, up to 6 cycles
Trial: NCT04522635
Drug: (100 ml of Albumin 25%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of 25g albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
Trial: NCT00167713
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02516605
Drug: Part 1: LJN452
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LJN452 capsules administered once daily for 28 days
Trial: NCT02516605
Drug: Part 1: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules administered once daily for 28 days
Trial: NCT02516605
Drug: Part 2: LJN452 Dose level 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LJN452 capsules administered once a day for 12 weeks
Trial: NCT02516605
Drug: Part 2: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to LJN452 administered once a day for 12 weeks
Trial: NCT02516605
Drug: Part 2: LJN452 Dose level 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LJN452
Trial: NCT00864968
Drug: Nabumetone 750 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fasting conditions
Trial: NCT00864968
Drug: Nabumetone 750 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Teva formulated products under fasting conditions
Trial: NCT00207363
Drug: induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg Intron 3.0mcg/kg/wk for 12 weeks then Peg interon 1.5mcg/kg/week for 36 weeks
Trial: NCT00408408
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2 orally
Trial: NCT00408408
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 IV
Trial: NCT00408408
Drug: doxorubicin hydrochloride (Adriamycin)
RxNorm normalized name: doxorubicin hydrochloride Injection [Adriamycin]
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 IV
Trial: NCT01164514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline.
Trial: NCT01353898
Drug: MK-1972
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1972 will be supplied as 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
Trial: NCT01353898
Drug: Placebo to MK-1972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as matching 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
Trial: NCT00904449
Drug: Oxymorphone ER
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg, 20mg, and 40mg PO
Trial: NCT04362241
Drug: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
RxNorm normalized name: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone Acetate 1% ophthalmic drops
Trial: NCT03942796
Drug: lyrica, vronogabic (pregabalin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients would receive oral pregabalin is initiated at a dose of 75 mg twice daily and titrated up to 600 mg as tolerated by the patient at 1,2,3 weeks
Trial: NCT02108158
Drug: Azzalure
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04235959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02646501
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug
Trial: NCT02167698
Drug: sedo-analgesia titration
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00261599
Drug: AQUAVAN® (fospropofol disodium) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00859495
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.
Trial: NCT01220024
Drug: Placebo collagen Sponge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo Collagen Sponge
Trial: NCT02219750
Drug: switch twice-daily insulin
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: compare two different insuiln regimen in basal insuln base and premixed insulin.~NovoMix 30, drug class:biphasic insulins Lantus, drug class: long-acting insuiln Levemir, durg class: long-acting insulin NovoRapid, drug class: rapid-acting insulin
Trial: NCT03570658
Drug: RO7049389
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7049389 will be administered orally either as a single dose (SAD) or as multiple doses defined by the SAD portion of the study (MAD).
Trial: NCT04611386
Drug: computerized tomography
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti Factor Xa level
Trial: NCT03570658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally at a dose and frequency matched to RO7049389.
Trial: NCT00181272
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00298506
Drug: Multitherapy
RxNorm normalized name: Niacinamide 1.0 g in 50 mL / Adenosine 0.02 g in 50 mL TOPICAL CREAM [rootree Mobitherapy Repair Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus,4mg/d, MMF 1.0g/d
Trial: NCT02030067
Drug: RX-3117
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02607904
Drug: GWP42003-P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Trial: NCT00158301
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive 12 weeks of treatment with antidepressant therapy. Responders to initial treatment will continue medication during the continuation phase (both treatment arms).
Trial: NCT02590627
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine
Trial: NCT03279731
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). It is designed to be identical to the pen used for liraglutide (Saxenda). Placebo product inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection
Trial: NCT02948998
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participants in this arm will be prescribed to take 20mg spironolactone orally and daily. Serum potassium concentration and creatinine and blood pressure will be monitored regularly to make the participants safe.
Trial: NCT04246996
Drug: gentamicin sulfate
RxNorm normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in the gentamicin arm will receive an bladder instillation of 80mg of gentamicin sulfate in 50 mL of normal saline through a standard-of-care Foley catheter.
Trial: NCT02875236
Drug: OctaplasLG®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OctaplasLG is an donor plasma product pooled from approximately 1000 single donor units. It possesses unique features when compared to standard fresh frozen plasma, such as having standardized concentrations of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen free. The manufacturing method of OctaplasLG removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation by immune neutralization. OctaplasLG should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma.
Trial: NCT02875236
Drug: Ringer-acetat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid used as standard of care.
Trial: NCT00265876
Drug: AZD0530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken daily every 4 weeks
Trial: NCT04235673
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally administered drops
Trial: NCT04049786
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose of simvastatin 40 mg are being administrated orally.
Trial: NCT03388450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition without omega 3 fatty acid.
Trial: NCT04391660
Drug: 0.5% sodium hypochlorite solution and 70% ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress preceded by an application of 70% ethanol with a sterile compress, for its immediate bactericidal action. 0.5% sodium hypochlorite solution will be applied once the alcohol has evaporated and the skin is visually dried. These same antiseptics will be used at each dressing change.
Trial: NCT03241485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline intrathecal given in the same manner as the intervention groups.
Trial: NCT01617824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for 4 days
Trial: NCT01329991
Drug: PLX5622
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo
Trial: NCT01329991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for PLX5622
Trial: NCT00746382
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream
Trial: NCT00602602
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04246684
Drug: 5FU; 2400 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2400 mg/m2, 46h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, 134 of therapy for Control arm
Trial: NCT00553319
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group
Trial: NCT04246684
Drug: 5FU, 250 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/m2 per day, civ, on day 1-14, day 22-35 of radiotherapy;
Trial: NCT04246684
Drug: 5FU, 2400 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2400 mg/m2,46h-civ, d64, d78, d92, d106, d120, d134 of therapy
Trial: NCT04246684
Drug: Folinic Acid, 400 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2h-civ day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapyfor Control arm; 400 mg/m2, 2h-civ d 64, d78, d92, d106, d120, d134 of therapy for experimental arm
Trial: NCT04246684
Drug: Capecitabine, 1000 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/m2 (twice daily) day1-14 every three weeks instead of 5FU optional
Trial: NCT04246684
Drug: Capecitabine, 825 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 825 mg/m2 bid, per os, on day 1-14, 22-35 of RT instead of 5FU optional
Trial: NCT03216525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To determine if placebo during radical cystectomy with urinary diversion results in faster return of bowel function.
Trial: NCT00508118
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: on bypass
Trial: NCT01701531
Drug: RBCPF
RxNorm normalized name: Recombinant Bovine Chondroitin Polysulfate Formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02751606
Drug: ferumoxtran-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ferumoxtran-10 will be administered intravenously one day prior to the MRI scan
Trial: NCT03373006
Drug: Axumin PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic amino acid uptake agent injection followed by imaging
Trial: NCT00720291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who are randomly assigned to receive a placebo will receive a placebo pill po bid for 7 days.
Trial: NCT00377273
Drug: fluorouracil cream 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01229592
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every three day lock using Ethanol(70%)in all the lumen(1ml/per lumen) of the Catheter
Trial: NCT05737927
Drug: Glucose 8 g coated beads (47% w/w)
RxNorm normalized name: glucose 47 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After an overnight fasting of about 10 hours, the subjects were administered 8 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
Trial: NCT05737927
Drug: Glucose 12 g coated beads (47% w/w)
RxNorm normalized name: glucose 47 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After an overnight fasting of about 10 hours, the subjects were administered 12 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
Trial: NCT05737927
Drug: Glucose 12 g uncoated beads
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After an overnight fasting of about 10 hours, the subjects were administered the uncoated Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
Trial: NCT05737927
Drug: Glucose 12 g coated beads (47% w/w)
RxNorm normalized name: glucose 47 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After an overnight fasting of at least 10 hours, the subjects were administered the new developed Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position. Treatment duration: Day 1 - Day 4
Trial: NCT01833351
Drug: IV Vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will begin by enrolling 3 people at each dose level and if there are any problems seen, we will enroll 3 more people to that dose to see if that problem happens again and this may total a maximum of 6 people. Therefore a maximum of 6 people may be enrolled at each of these Vitamin C dose levels, 1 gram, 5 grams, 10 grams, 25 grams, 50 grams, 75 grams, and 100 grams.~If you are eligible for the study and decide to participate, the total time involved could be approximately 4 weeks.